Cambridge Nutritional Sciences Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B1VCP282
GBP
0.02
0 (-6.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

  • NET SALES(Q) Fallen at -16.21%
2

With ROE of -2.32%, it has a very attractive valuation with a 0.60 Price to Book Value

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 5 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

-4.03%

stock-summary
Price to Book

0.45

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.46%
0%
-38.46%
6 Months
-38.46%
0%
-38.46%
1 Year
-37.5%
0%
-37.5%
2 Years
-24.53%
0%
-24.53%
3 Years
-41.18%
0%
-41.18%
4 Years
-92.45%
0%
-92.45%
5 Years
-96.26%
0%
-96.26%

Cambridge Nutritional Sciences Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.10%
EBIT Growth (5y)
8.93%
EBIT to Interest (avg)
-1.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
0.72
Tax Ratio
41.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.14%
ROE (avg)
2.47%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.60
EV to EBIT
-2.26
EV to EBITDA
-2.26
EV to Capital Employed
0.33
EV to Sales
0.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-9.98%
ROE (Latest)
-2.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Cambridge Nutritional Sciences Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is -11.76% vs 25.00% in Mar 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -128.57% vs -450.00% in Mar 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.50",
          "val2": "8.50",
          "chgp": "-11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.30",
          "chgp": "-66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-1.40",
          "chgp": "-128.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-368.30%",
          "val2": "-68.20%",
          "chgp": "-30.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Mar'23stock-summary
Mar'23
Mar'22
Change(%)
Net Sales
7.50
8.50
-11.76%
Operating Profit (PBDIT) excl Other Income
-2.20
-0.00
Interest
0.00
0.00
Exceptional Items
-0.50
-0.30
-66.67%
Consolidate Net Profit
-3.20
-1.40
-128.57%
Operating Profit Margin (Excl OI)
-368.30%
-68.20%
-30.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2023 is -11.76% vs 25.00% in Mar 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -128.57% vs -450.00% in Mar 2022

stock-summaryCompany CV
About Cambridge Nutritional Sciences Plc stock-summary
stock-summary
Cambridge Nutritional Sciences Plc
Pharmaceuticals & Biotechnology
Omega Diagnostics Group PLC is a medical diagnostics company. The Company's segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. It offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.
Company Coordinates stock-summary
Company Details
Omega House, Hillfoots Business Village, Scotland ALVA None : FK12 5DQ
Registrar Details